For decades, cefepime has been a quiet constant in hospital medicine — a broad-spectrum antibiotic trusted to fight the infections that threaten lives. Now, a major study has placed that trust under scrutiny, finding that adults treated with cefepime face higher mortality rates than those receiving comparable antibiotics in the same class. The finding does not arrive without precedent, but its scale gives it a gravity that may compel medicine to reckon with what it thought it already knew.
Major Study Links Common Antibiotic Cefepime to Higher Mortality Risk
The study indicates higher mortality rates in adults treated with cefepime compared to alternative antibiotics, affecting patient survival outcomes.